Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol glycan anchor biosynthesis class Y protein (PIGY) is a subunit of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex, which catalyzes the initial step in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors in the endoplasmic reticulum[1][3]. GPI anchors are glycolipid modifications used to covalently anchor a wide range of proteins to the cell membrane, impacting cellular functions such as cell-cell interactions and protein localization[1][3]. PIGY may act by regulating the catalytic subunit PIGA in this multicomponent enzyme complex[3]. Mutations in PIGY are associated with rare congenital disorders, specifically hyperphosphatasia with impaired intellectual development syndrome 6 (HPMRS6)[3]. No direct drugs are known to target PIGY, and it is not typically considered a standalone therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol glycan anchor biosynthesis class Y protein (PIGY).